Research location
Lobos
Buenos Aires, Argentina
Advertisement
Research activity in Lobos
Buenos Aires, ArgentinaCureCurrent currently publishes aggregate city-level research activity for this location: 8 trials and 8 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Lobos
8 linked trials · page 1 of 1Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic PhenotypeNCT07190209 · 2025-09-16 · 1 site observation
RECRUITING
Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)NCT06961214 · 2025-06-23 · 1 site observation
RECRUITING
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk AsthmaNCT06676319 · 2024-11-07 · 1 site observation
ACTIVE_NOT_RECRUITING
Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With AsthmaNCT06609239 · 2024-09-30 · 1 site observation
ENROLLING_BY_INVITATION
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)NCT05878769 · 2023-06-28 · 1 site observation
ACTIVE_NOT_RECRUITING
Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 InflammationNCT04456673 · 2020-07-06 · 1 site observation
COMPLETED
Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With AsthmaNCT03248128 · 2017-10-20 · 1 site observation
COMPLETED
A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)NCT03034915 · 2017-06-16 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.